Effects of Chestnuts on Postprandial Glycaemic Response

Condition(s) studied

Investigational drug(s) / intervention(s)

Chestnut meal: Participants will receive an isocaloric baked meal with chestnut flour.

Control meal: Participants will receive an isocaloric baked meal without chestnut flour.

Study summary

Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols.

Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.

Eligibility

Primary outcome measure(s)

• Postprandial blood glucose incremental area under the curve (iAUC) — Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
  Difference in postprandial blood glucose iAUC
• Postprandial plasma insulin incremental area under the curve (iAUC) — Three hour insulin iAUC will be calculated from seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
  Difference in postprandial plasma insulin iAUC.

Trial sites (1)

More Monash University trials in Australia